Urine-Based Chromosomal Probe Detection for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prostate cancer, such as PSA testing and trans-rectal prostate biopsies, suffer from high false positive rates, low clinical specificity, and are invasive, making them inadequate for accurate and less invasive early detection.
Innovation Solution
A method involving the use of urine samples containing prostate cells, where a set of chromosome-specific probes labeled with detectable markers are hybridized to the cells, allowing for the detection of polysomic prostate cells indicative of prostate carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA testing is used for prostate cancer screening, then early detection capability is improved, but false positive rate increases and clinical specificity decreases
Solution Approach 1:
The invention segments the detection process into multiple independent chromosomal probe tests (chromosome 6, 8, 10, and Y chromosome probes) rather than relying on a single PSA test. Each probe targets specific chromosomal abnormalities associated with prostate cancer, allowing for more precise characterization of prostate cells and reduction of false positives while maintaining early detection capability.
Solution Approach 2:
The invention changes the detection parameter from measuring PSA protein levels to detecting chromosomal copy number abnormalities (polysomy) through fluorescent in situ hybridization. This parameter change from biochemical marker to genetic marker improves measurement precision and clinical specificity while preserving the ability to detect early-stage cancer.
2Measurement precision
If trans-rectal prostate biopsies are used to detect prostate cancer, then detection accuracy is improved, but patient morbidity and mortality increase due to invasiveness
Solution Approach 1:
The invention uses urine as an intermediary medium to obtain prostate cells for analysis. Instead of directly inserting biopsy instruments into the prostate gland, the method collects cells that are naturally shed into the urine or can be obtained through less invasive procedures like transperineal massage, thereby reducing patient trauma while maintaining detection accuracy.
Solution Approach 2:
The invention replaces the mechanical biopsy system (needles, forceps, and surgical instruments) with a molecular detection system using fluorescent in situ hybridization probes. This substitution eliminates the need for invasive mechanical tissue sampling while achieving comparable or superior detection accuracy through chromosomal analysis of shed prostate cells.
3Reliability
If trans-rectal prostate biopsies are used, then cancer detection capability is improved, but false negative rate increases because the entire prostate is not sampled
Solution Approach 1:
The invention makes the detection method universal by analyzing chromosomal abnormalities that are systemically present in prostate cells throughout the gland. Since chromosomal polysomy is a fundamental genetic alteration affecting all prostate cells derived from the cancerous focus, a single urine sample can reflect the overall prostate status, eliminating the sampling error inherent in localized biopsies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a more accurate and less invasive means of detecting prostate cancer, with improved sensitivity and specificity compared to existing techniques, as evidenced by the high area under the curve (AUC) values in receiver operating characteristic (ROC) curves.
Implementation Method 1
hybridizing a set of at least two chromosome-specific probes to the prostate cells, wherein each chromosome-specific probe has a detectable label and is specific for a different human chromosome
Data Source
AI summary
The present invention provides methods for diagnosing whether a human subject has a prostate carcinoma, methods for differentiating a high grade prostate cancer from a low grade prostate cancer in a human subject having a prostate carcinoma, and kits for detecting prostate cancer cells in a sample from a human subject.